Q1 2026 Performance: Steady Revenue Growth and Significant Cash Reserve Increase
Plant cell cultivation biotechnology firm BioHarvest Sciences recently released its financial results for the first quarter of 2026. The data shows that the company's Q1 revenue reached $8.5 million, marking an 8% year-over-year increase and slightly surpassing market expectations. Gross profit rose to $5 million, with a gross margin of 59%. Cash and deposits saw a substantial rise from $3.4 million in the same period last year to $20.2 million.
The net loss was $2.6 million, equivalent to a loss per share of $0.11. This result outperformed the market consensus of a $0.12 loss per share and showed an improvement from the $0.13 loss per share reported in the prior-year period.
Full-Year 2026 Guidance: Clear Targets for D2C and CDMO Businesses
During the earnings call, CEO Zaki Rakib reaffirmed the company's full-year 2026 performance guidance. For the core VINIA direct-to-consumer business, the company anticipates annual revenue between $38 million and $42 million. Adjusted EBITDA profit is projected to be in the range of $0.5 million to $2 million, indicating a move into profitability.
Regarding the Contract Development and Manufacturing Organization business, the company expects service revenue from existing and new projects to be between $4 million and $6 million. Total CDMO revenue, inclusive of internal VINIA production, is forecasted to reach $12 million to $14 million. At the overall corporate level, the adjusted EBITDA loss is anticipated to be between $4 million and $5 million.
Fragrance Production Target: Mass Production Commencement in H2 2027
The company has achieved a significant breakthrough in the fragrance sector. In May 2026, BioHarvest signed a $1.2 million Phase 2 contract for the development of rare, fragrance-producing plants for application in the global flavor and fragrance industry. This contract follows the completion of Phase 1 cell bank establishment in March 2026. Phase 2 is expected to last six to nine months, culminating in the production of sufficient raw materials for commercial testing.
The company stated its target is to initiate mass production of fragrances in the second half of 2027, coinciding with the operational launch of a new production facility within the company's campus. Under the agreement, BioHarvest will retain 20% ownership of the developed compositions and will serve as the manufacturing entity.
Management emphasized that this milestone signifies the company has overcome key technical hurdles. This progress is expected to facilitate the launch of more fragrance projects, aiding the company's expansion into the high-end fragrance market, valued at $23 billion.
Comments